This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2008 by Hospital Sao Domingos.
Recruitment status was:  Recruiting
Information provided by:
Hospital Sao Domingos Identifier:
First received: September 4, 2008
Last updated: September 8, 2008
Last verified: September 2008
The purpose of this prospective randomized controlled trial was to compare intensive insulin therapy with a carbohydrate restrictive strategy in patients with acute ischemic stroke evaluating the outcome through the Glasgow Outcome Scale Extended, hospital mortality and NIHSS during the ICU stay.

Condition Intervention Phase
Acute Ischemic Stroke Other: Carbohydrate restrictive strategy Drug: Intensive insulin therapy Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

Resource links provided by NLM:

Further study details as provided by Hospital Sao Domingos:

Primary Outcome Measures:
  • Neurological outcome through the Glasgow Outcome Scale Extended [ Time Frame: At least 4 months after hospital discharge ]

Secondary Outcome Measures:
  • NIHSS during ICU stay [ Time Frame: ICU stay ]
  • Hospital mortality [ Time Frame: Hospital stay ]

Estimated Enrollment: 70
Study Start Date: June 2007
Arms Assigned Interventions
Experimental: 1
Carbohydrate restrictive strategy
Other: Carbohydrate restrictive strategy
Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
Active Comparator: 2
Intensive insulin therapy
Drug: Intensive insulin therapy
Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with acute ischemic stroke defined as: Abrupt onset of focal neurologic deficit
  • No evidence of intracranial hemorrhage at non-contrasted CT scan.

Exclusion Criteria:

  • Age below 18
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00747279

Contact: JOSE R AZEVEDO, MD 55 98 32275735

Hospital Sao Domingos Recruiting
Sao Luis, MA, Brazil, 65060-642
Contact: JOSE R AZEVEDO, MD    55 98 32275735   
Principal Investigator: JOSE R AZEVEDO, MD         
Sponsors and Collaborators
Hospital Sao Domingos
  More Information Identifier: NCT00747279     History of Changes
Other Study ID Numbers: HSD001
Study First Received: September 4, 2008
Last Updated: September 8, 2008

Additional relevant MeSH terms:
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 22, 2017